ACCRUED LIABILITIES Accrued liabilities consisted of the following: | | | | | | | | | | | | | | | | | June 30, 2020 | | December 31, 2019 | | | | | | | | | | | | | | | | | | (in thousands) | | | Accrued outsourced clinical trials and preclinical studies | $ | 959 | | | $ | 2,259 | | Accrued employee compensation and related taxes | 686 | | | 508 | | Operating lease liability | 397 | | | — | | Restructuring liability | 377 | | | 1,515 | | Accrued legal fees and expenses | 311 | | | 284 | | Accrued other professional service fees | 105 | | | 254 | | Value of liability-classified stock purchase warrants | 100 | | | 100 | | | | | | Deferred and accrued facility lease obligations | — | | | 66 | | | | | | | | | | Other accrued liabilities | 85 | | | 122 | | Total accrued liabilities | $ | 3,020 | | | $ | 5,108 | |
|